Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Thieme

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Immunology|July 12, 2023
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvantGwenn Waerlop, Yorick Janssens, Bart Jacobs, et al.
The New Phytologist|June 29, 2012
Analysis of new type III effectors from Xanthomonas uncovers XopB and XopS as suppressors of plant immunitySebastian Schulze, Sabine Kay, Daniela Büttner, et al.
Frontiers in Immunology|October 24, 2022
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccineIsabel Leroux-Roels, Cathy Maes, Jasper Joye, et al.
Biomed Research International|October 2, 2015
Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular LymphomaDaniel Tusé, Nora Ku, Maurizio Bendandi, et al.
Journal of Bacteriology|October 21, 2005
Insights into genome plasticity and pathogenicity of the plant pathogenic bacterium Xanthomonas campestris pv. vesicatoria revealed by the complete genome sequenceFrank Thieme, Ralf Koebnik, Thomas Bekel, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Frontiers in Immunology|July 12, 2023
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvantGwenn Waerlop, Yorick Janssens, Bart Jacobs, et al.
The New Phytologist|June 29, 2012
Analysis of new type III effectors from Xanthomonas uncovers XopB and XopS as suppressors of plant immunitySebastian Schulze, Sabine Kay, Daniela Büttner, et al.
Frontiers in Immunology|October 24, 2022
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccineIsabel Leroux-Roels, Cathy Maes, Jasper Joye, et al.
Biomed Research International|October 2, 2015
Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular LymphomaDaniel Tusé, Nora Ku, Maurizio Bendandi, et al.
Journal of Bacteriology|October 21, 2005
Insights into genome plasticity and pathogenicity of the plant pathogenic bacterium Xanthomonas campestris pv. vesicatoria revealed by the complete genome sequenceFrank Thieme, Ralf Koebnik, Thomas Bekel, et al.
Pageof 2